#news #biotech Gilead rocked by phase 3 failure of selonsertib in NASH

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Gilead rocked by phase 3 failure of selonsertib in NASH .A phase 3 trial of Gilead’s NASH prospect selonsertib has bombed. The ASK1 inhibitor was no better than placebo at improving fibrosis, wiping out hopes that selonsertib would spearhead Gilead’s push into a new market.

from FierceBiotech: Biotech http://bit.ly/2GDDGJC